Today, the two most successfully exploited immune checkpoints are CD279, called programmed cell death protein 1 (PD-1), expressed on tumour infiltrating lymphocytes, B cells, NK cells, and myeloid cells; and its ligand, CD274, called programmed death-ligand 1 (PD-L1), expressed on tumour cells. Here, PDCD1 is linked to neoplasm.